article
Stem Cells: In-Depth Focus 2014
In this free-to-view Stem Cells In-Depth Focus: Mesenchymal stem cells in cancer therapy - our chance to take charge, and Ovarian cancer stem cells - an essential target for durable remission...
List view / Grid view
Stem Cells
news
Novartis announces global research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
news
Scientists succeed in growing human brain tissue in “test tubes”
28 August 2013 | By IMBA - Institute of Molecular Biotechnology GmbH
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory...
article
Stem Cells In-Depth Focus 2013
In this Stem Cells In-Depth Focus: The promise held by induced pluripotent stem cells for research and regenerative medicine; Workshop preview – Cell based assays for screening; Cardiac stem cells; Stem Cells Roundtable...
news
Lonza and OncoMed Pharmaceuticals sign a process development and manufacturing collaboration and multi-product GS license agreement
Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.
news
Lonza awarded contract to generate clinical grade iPSCs by the NIH CRM
The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…
news
Lonza announces license agreement with iPS Academia Japan
Lonza has entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By entering this agreement, Lonza demonstrates its commitment to the field of regenerative medicine and reinforces its belief that iPSCs are a key platform technology for the cell…
article
Stem Cells In-Depth Focus 2012
In this Stem Cells In-Depth Focus: Stem cell therapies: Assuring safety; Role of pluripotent stem cells in neurotoxicology testing: Impacts and applied innovations...
article
Drug screens on human stem cells: From understanding cell biology to predicting drug toxicity
19 October 2011 | By Ivana Barbaric and Peter W. Andrews, Centre for Stem Cell Biology, University of Sheffield
The Canadian physician William Osler said: “The person who takes medicine must recover twice, once from the disease and once from the medicine.” Indeed, all medicines have side effects – some of which may complicate a patient’s treatment, or in extreme cases may even be fatal. Of concern is the…
article
In search of the Holy Grail: Engineering the stem cell niche
19 April 2011 | By Janet L. Paluh, Associate Professor Nanobioscience, College of Nanoscale Science and Engineering, University at Albany SUNY and Guohao Dai and Douglas B. Chrisey, Biomedical Engineering, Rensselaer Polytechnic Institute
There is no other biomedical frontier that offers the stunning potential of human pluripotent stem cells and their progenitors in therapeutic applications to ease human suffering or in their ability to provide insights into development and diseases. Cell plasticity for reprogramming has revealed new opportunities in cell-based therapies and informed…
news
Clinical trial success for Crohn’s Disease cell therapy
30 March 2011 | By UK National Stem Cell Network (UKNSCN)
Professor Miguel Forte will describe research into a new cell therapy at the UK National Stem Cell Network annual science meeting...
article
Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine
9 May 2010 | By Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee
They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are…
article
2009: A landmark year for stem cells
22 February 2010 | By
It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge…
article
Combining perspectives: Multiscale integration of Stem Cell research
12 December 2009 | By
The promise of stem cell-based therapy is predicated on harnessing the plasticity of stem cell phenotypes to repair or replace damaged tissues. As technologies for detecting, isolating, modifying, and tracking stem cells improve, the very definition of what constitutes a stem cell is now an open question. Addressing this fundamental…
article
Stem cells and regenerative medicine world congress 2010
12 December 2009 | By
The 4th annual Stem Cells World Congress and exhibition will be held in South San Francisco, the Birthplace of Biotechnology. This year there are two parallel tracks focused specifically on...
